Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
In a room full of avowed capitalists, policies that sound to some like socialism are bound not to go over well.Delivering Alpharead more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
Trump has criticized Facebook numerous times since becoming president, most recently posting on Twitter that the company's proposed digital currency, libra, will "have little...Technologyread more
Republicans and Democrats have long since separated themselves by ideology, leaving each more uniformly conservative or liberal than ever. And now a new data analysis by the...Politicsread more
At least in terms of monetary policy, Pence says should be taking after other regions who keep their benchmark interest rates near zero.Delivering Alpharead more
The Pentagon on Thursday said the recent attack on Saudi Arabian oil facilities were "sophisticated" and represented a "dramatic escalation" in tensions within the region.Defenseread more
The flap illustrates the growing distrust of the YouTube community, and willingness to assume the worst in light of unclear communication.Technologyread more
Four years ago Microsoft had just two women on its board. Walmsley is now the fifth.Technologyread more
AT&T isn't focused on selling or divesting DirecTV, despite pressure from stakeholder Elliott Management, sources tell CNBC.Technologyread more
Patrick Shyu, a former tech lead at Google, has posted a series of videos making fun of Facebook, where he worked as a software engineer until last month.Technologyread more
Emergent BioSolutions said Tuesday that the U.S. Food and Drug Administration has completed its pre-approval inspection of Emergent's large-scale facility for making BioThrax, a vaccine for pre-exposure protection against anthrax.
"Emergent is pleased to have reached this critical milestone in our BioThrax comparability program," Adam Havey, executive vice president and president of biodefense division at Emergent, said in the press release.
The company said it looks forward to "timely completing" the process of securing its FDA license for the facility, which is in Lansing, Michigan. A decision is expected by August, the company said.
BioThrax is the only approved anthrax vaccine in the U.S. The company has been supplying it to the Centers for Disease Control and Prevention as part of an effort to develop a U.S. stockpile in the event of a terrorist attack.
Anthrax is an infection caused by a spore-forming bacterium. It mainly effects animals, but humans can contract the infection through contact with infected animals or inhaling spores. Inhaled anthrax can be hard to treat and can be fatal.
Emergent's stock has dropped slightly this year, falling more than 1 percent. The company's shares were mostly unchanged, but were moving back and forth between positive and negative territory.